Boston Scientific Catheter Recall Issued Over Tip Detachment Risks

Thousands of Boston Scientific catheters have been recalled because of problems with the catheter tip, which may detach during use, posing an increased risk of serious injuries and emergency surgery to remove the catheter.

The FDA announced the Boston Scientific catheter recall on Tuesday, due to an unreasonable risk of tip detachments, which may cause an obstruction in a patient’s blood vessels.

The recall involves Boston Scientific Corporation IMAGER II 5F Angiographic Catheters, which are used to provide a pathway to deliver contrast agents to blood vessels, including carotid arteries.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

According to the FDA, the tips of the catheters have the potential to become detached during a patient procedure or during procedure preparation, especially during extraction, which would require additional surgical intervention to remove the catheter tip in the patient’s blood vessel, increasing time in the hospital.

The FDA warns healthcare providers and surgeons that, in the event of the catheter tip becoming detached during a procedure, patients could experience serious and life-threatening health consequences, including obstruction of blood flow, stroke, or death.

The recall involves approximately 6,130 IMAGER II 5F Angiographic Catheters manufactured by Boston Scientific Corporation of Marlborough, Massachusetts. They were distributed to healthcare and surgical centers across the nation from July 16, 2018 to November 26, 2019.

The FDA advises healthcare professionals to stop using the impacted products immediately and to remove them from all hospital inventory.

On February 11, Boston Scientific issued a letter to customers informing them on the potential issue and gave instructions on how to complete the Verification Form to include that quantity and lot numbers in the facility’s possession.

On April 7, the FDA categorized the letter as a Class I recall, the most serious classification, indicating the agency believes the use of the product poses a risk of serious adverse health consequences and even death.

Customers with additional questions or concerns regarding the recall are encouraged to contact their local Boston Scientific sales representative at BSCFieldActionCenter@bsci.com. Customers who have experienced adverse reactions or quality problems with the devices are being asked to report them to the FDA ‘s MedWatch adverse event reporting program.

Written by: Russell Maas

Managing Editor & Senior Legal Journalist

Russell Maas is a paralegal and the Managing Editor of AboutLawsuits.com, where he has reported on mass tort litigation, medical recalls, and consumer safety issues since 2010. He brings legal experience from one of the nation’s leading personal injury law firms and oversees the site’s editorial strategy, including SEO and content development.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A federal judge has scheduled a series of case management conferences throughout 2026 as the parties prepare for five “pilot” bellwether trials, which are expected to begin in late 2026 or early 2027.
An increasing number of Ozempic and Mounjaro users are reporting sudden, irreversible vision loss from NAION side effects, prompting new lawsuits and a federal push to consolidate blindness claims into a dedicated multidistrict litigation.
Cartiva is urging federal judges to reject consolidation of toe-implant lawsuits, arguing that an MDL would interfere with individual claim resolutions that the company says are already being handled efficiently outside of court.